Found: 36
Select item for more details and to access through your institution.
Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 3, p. E83, doi. 10.1002/ajh.26434
- By:
- Publication type:
- Article
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 9, p. 1120, doi. 10.1002/ajh.26261
- By:
- Publication type:
- Article
Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 6, p. 708, doi. 10.1002/ajh.26172
- By:
- Publication type:
- Article
Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN‐003/MYX.1 single arm phase II trial.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 5, p. 552, doi. 10.1002/ajh.26147
- By:
- Publication type:
- Article
Retrospective study of treatment patterns and outcomes post‐lenalidomide for multiple myeloma in Canada.
- Published in:
- European Journal of Haematology, 2021, v. 107, n. 4, p. 416, doi. 10.1111/ejh.13678
- By:
- Publication type:
- Article
A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
- Published in:
- European Journal of Haematology, 2021, v. 107, n. 3, p. 333, doi. 10.1111/ejh.13671
- By:
- Publication type:
- Article
The impact of lenalidomide maintenance on second‐line chemotherapy in transplant eligible patients with multiple myeloma.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 5, p. 673, doi. 10.1111/ejh.13596
- By:
- Publication type:
- Article
Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis.
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. 608, doi. 10.1016/j.clml.2022.03.002
- By:
- Publication type:
- Article
Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database.
- Published in:
- Current Oncology, 2022, v. 29, n. 3, p. 1575, doi. 10.3390/curroncol29030132
- By:
- Publication type:
- Article
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
- Published in:
- 2022
- By:
- Publication type:
- journal article
MRD negativity: considerations for older adults with multiple myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00939-y
- By:
- Publication type:
- Article
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00905-8
- By:
- Publication type:
- Article
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00888-6
- By:
- Publication type:
- Article
Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00883-x
- By:
- Publication type:
- Article
High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors: The Alberta experience.
- Published in:
- Canadian Urological Association Journal, 2024, v. 18, n. 3, p. E73, doi. 10.5489/cuaj.8493
- By:
- Publication type:
- Article
Systemic Amyloidosis in England: an epidemiological study.
- Published in:
- British Journal of Haematology, 2013, v. 161, n. 4, p. 525, doi. 10.1111/bjh.12286
- By:
- Publication type:
- Article
Long‐term follow‐up of outcomes including progression‐free survival 2 in patients with transplant‐ineligible multiple myeloma in the real‐world practice: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) database
- Published in:
- EJHaem, 2024, v. 5, n. 3, p. 474, doi. 10.1002/jha2.894
- By:
- Publication type:
- Article
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial.
- Published in:
- EJHaem, 2023, v. 4, n. 4, p. 995, doi. 10.1002/jha2.759
- By:
- Publication type:
- Article
Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment.
- Published in:
- EJHaem, 2022, v. 3, n. 4, p. 1270, doi. 10.1002/jha2.572
- By:
- Publication type:
- Article
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database.
- Published in:
- EJHaem, 2022, v. 3, n. 4, p. 1252, doi. 10.1002/jha2.559
- By:
- Publication type:
- Article
Frequency, Timing, and Predictors of Palliative Care Consultation in Patients with Advanced Cancer at a Tertiary Cancer Center: Secondary Analysis of Routinely Collected Health Data.
- Published in:
- Oncologist, 2020, v. 25, n. 8, p. 722, doi. 10.1634/theoncologist.2019-0384
- By:
- Publication type:
- Article
Part 7: Monoclonal gammopathy for the non-hematologist oncologist.
- Published in:
- Oncology Exchange, 2013, v. 12, n. 3, p. 15
- By:
- Publication type:
- Article
Frequent Occurrence of Highly Expanded but Unrelated B-Cell Clones in Patients with Multiple Myeloma
- Published in:
- PLoS ONE, 2013, v. 8, n. 5, p. 1, doi. 10.1371/journal.pone.0064927
- By:
- Publication type:
- Article
Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 1, p. 93, doi. 10.1111/bjh.18172
- By:
- Publication type:
- Article
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 4, p. 784, doi. 10.1111/bjh.17541
- By:
- Publication type:
- Article
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
- Published in:
- British Journal of Haematology, 2014, v. 166, n. 6, p. 842, doi. 10.1111/bjh.12973
- By:
- Publication type:
- Article
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
- Published in:
- British Journal of Haematology, 2014, v. 165, n. 5, p. 842, doi. 10.1111/bjh.12973
- By:
- Publication type:
- Article
Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis.
- Published in:
- British Journal of Haematology, 2013, v. 162, n. 6, p. 856, doi. 10.1111/bjh.12433
- By:
- Publication type:
- Article
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 4, p. 4357, doi. 10.1002/cam4.5245
- By:
- Publication type:
- Article
Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.826342
- By:
- Publication type:
- Article
Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model.
- Published in:
- Cancers, 2018, v. 10, n. 6, p. 206, doi. 10.3390/cancers10060206
- By:
- Publication type:
- Article
Exploring participant perceptions of a virtually supported home exercise program for people with multiple myeloma using a novel eHealth application: a qualitative study.
- Published in:
- Supportive Care in Cancer, 2023, v. 31, n. 5, p. 1, doi. 10.1007/s00520-023-07762-y
- By:
- Publication type:
- Article